Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BioNexus Gene Lab (BGLC) Assets Average (2019 - 2025)

BioNexus Gene Lab's Assets Average history spans 7 years, with the latest figure at $8.4 million for Q4 2025.

  • Quarterly results put Assets Average at $8.4 million for Q4 2025, down 21.26% from a year ago — trailing twelve months through Dec 2025 was $8.4 million (down 21.26% YoY), and the annual figure for FY2025 was $9.8 million, down 9.83%.
  • Assets Average for Q4 2025 was $8.4 million at BioNexus Gene Lab, down from $8.5 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $11.4 million in Q4 2023 to a low of $8.0 million in Q2 2023.
  • The 5-year median for Assets Average is $9.6 million (2021), against an average of $9.6 million.
  • The sharpest move saw Assets Average surged 826.62% in 2021, then decreased 23.01% in 2025.
  • Year by year, Assets Average stood at $9.7 million in 2021, then dropped by 14.48% to $8.3 million in 2022, then skyrocketed by 38.26% to $11.4 million in 2023, then dropped by 6.28% to $10.7 million in 2024, then dropped by 21.26% to $8.4 million in 2025.
  • According to Business Quant data, Assets Average over the past three periods came in at $8.4 million, $8.5 million, and $9.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.